Adeno-associated virus type 2 in US children with acute severe hepatitis.

Autor: Servellita V; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Sotomayor Gonzalez A; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Lamson DM; Wadsworth Center, New York State Department of Health, David Axelrod Institute, Albany, NY, USA., Foresythe A; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Huh HJ; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Bazinet AL; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA., Bergman NH; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA., Bull RL; Federal Bureau of Investigation Laboratory Division/Scientific Response and Analysis Unit, Quantico, VA, USA., Garcia KY; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA., Goodrich JS; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA., Lovett SP; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA., Parker K; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA., Radune D; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA., Hatada A; California Department of Public Health, Richmond, CA, USA., Pan CY; California Department of Public Health, Richmond, CA, USA., Rizzo K; California Department of Public Health, Richmond, CA, USA., Bertumen JB; California Department of Public Health, Richmond, CA, USA.; Centers for Disease Control and Prevention, Atlanta, CA, USA., Morales C; California Department of Public Health, Richmond, CA, USA., Oluniyi PE; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Nguyen J; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Tan J; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Stryke D; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA., Jaber R; Florida Department of Health, Tallahassee, FL, USA., Leslie MT; Illinois Department of Public Health, Chicago, IL, USA., Lyons Z; North Carolina Department of Health and Human Services, Raleigh, NC, USA., Hedman HD; Centers for Disease Control and Prevention, Atlanta, CA, USA.; South Dakota Department of Health, Pierre, SD, USA., Parashar U; Centers for Disease Control and Prevention, Atlanta, CA, USA., Sullivan M; Association for Public Health Laboratories, Silver Spring, MD, USA., Wroblewski K; Association for Public Health Laboratories, Silver Spring, MD, USA., Oberste MS; Centers for Disease Control and Prevention, Atlanta, CA, USA., Tate JE; Centers for Disease Control and Prevention, Atlanta, CA, USA., Baker JM; Centers for Disease Control and Prevention, Atlanta, CA, USA., Sugerman D; Centers for Disease Control and Prevention, Atlanta, CA, USA., Potts C; Centers for Disease Control and Prevention, Atlanta, CA, USA., Lu X; Centers for Disease Control and Prevention, Atlanta, CA, USA., Chhabra P; Centers for Disease Control and Prevention, Atlanta, CA, USA., Ingram LA; Alabama Department of Public Health, Montgomery, AL, USA., Shiau H; University of Alabama at Birmingham, Birmingham, AL, USA., Britt W; University of Alabama at Birmingham, Birmingham, AL, USA., Gutierrez Sanchez LH; University of Alabama at Birmingham, Birmingham, AL, USA., Ciric C; Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA., Rostad CA; Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA., Vinjé J; Centers for Disease Control and Prevention, Atlanta, CA, USA., Kirking HL; Centers for Disease Control and Prevention, Atlanta, CA, USA., Wadford DA; California Department of Public Health, Richmond, CA, USA., Raborn RT; National Biodefense Analysis and Countermeasures Center (NBACC), Frederick, MD, USA., St George K; Wadsworth Center, New York State Department of Health, David Axelrod Institute, Albany, NY, USA.; Department of Biomedical Science, University at Albany, SUNY, Albany, NY, USA., Chiu CY; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA. charles.chiu@ucsf.edu.; Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, USA. charles.chiu@ucsf.edu.; Chan-Zuckerberg Biohub, San Francisco, CA, USA. charles.chiu@ucsf.edu.
Jazyk: angličtina
Zdroj: Nature [Nature] 2023 May; Vol. 617 (7961), pp. 574-580. Date of Electronic Publication: 2023 Mar 30.
DOI: 10.1038/s41586-023-05949-1
Abstrakt: As of August 2022, clusters of acute severe hepatitis of unknown aetiology in children have been reported from 35 countries, including the USA 1,2 . Previous studies have found human adenoviruses (HAdVs) in the blood from patients in Europe and the USA 3-7 , although it is unclear whether this virus is causative. Here we used PCR testing, viral enrichment-based sequencing and agnostic metagenomic sequencing to analyse samples from 16 HAdV-positive cases from 1 October 2021 to 22 May 2022, in parallel with 113 controls. In blood from 14 cases, adeno-associated virus type 2 (AAV2) sequences were detected in 93% (13 of 14), compared to 4 (3.5%) of 113 controls (P < 0.001) and to 0 of 30 patients with hepatitis of defined aetiology (P < 0.001). In controls, HAdV type 41 was detected in blood from 9 (39.1%) of the 23 patients with acute gastroenteritis (without hepatitis), including 8 of 9 patients with positive stool HAdV testing, but co-infection with AAV2 was observed in only 3 (13.0%) of these 23 patients versus 93% of cases (P < 0.001). Co-infections by Epstein-Barr virus, human herpesvirus 6 and/or enterovirus A71 were also detected in 12 (85.7%) of 14 cases, with higher herpesvirus detection in cases versus controls (P < 0.001). Our findings suggest that the severity of the disease is related to co-infections involving AAV2 and one or more helper viruses.
(© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: